Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E CD274 over exp |
Therapy | Dabrafenib + Trametinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E CD274 over exp | lung adenocarcinoma | predicted - sensitive | Dabrafenib + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, second-line treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in a clinical response lasting at least 5 years in a patient with lung adenocarcinoma harboring BRAF V600E and high CD274 (PD-L1) expression (TPS=100%) who did not respond to first-line Keytruda (pembrolizumab) (PMID: 38429896). | 38429896 |
PubMed Id | Reference Title | Details |
---|---|---|
(38429896) | Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report. | Full reference... |